Stockwinners Market Radar for December 11, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EST Cathie Wood's ARK Investment bought 424.5K shares of Tempus AI today

19:26 EST AppLovin CEO sells $14.47M in common stock - In a regulatory filing, AppLovin disclosed that its CEO Adam Foroughi sold 43.5K shares of common stock on December 10th in a total transaction size of $14.47M.

19:09 EST JFrog director sells $1.07M in common stock - In a regulatory filing, JFrog disclosed that its director Frederic Simon sold 35K shares of common stock on December 10th in a total transaction size of $1.07M.

18:32 EST NorthView Acquisition receives late filing notice from Nasdaq - NorthView Acquisition has received a notice from Nasdaq stating that because the company has not yet filed its Form 10-Q for the period ended September 30, the company is no longer in compliance with Nasdaq Listing Rule 5250(c) which requires listed companies to timely file all required periodic financial reports with the SEC. This notification has no immediate effect on the listing of the company's shares on Nasdaq. However, if the company fails to timely regain compliance with the Nasdaq Listing Rule, the company's securities will be subject to delisting from Nasdaq. The company expects to file its Form 10-Q within the 60-day period, which would eliminate the need for the company to submit a formal plan to regain compliance.

18:08 EST TAT Technologies signs 5-year, $17M MRO agreement with cargo carrier - TAT Technologies has signed a five-year agreement with a major North American cargo carrier. TAT will provide repair and overhaul services under an MRO agreement for auxiliary power units on the Carriers' Boeing 757 and 767 aircraft. The total contract value over the duration of the agreement is estimated at approximately $17M.

18:01 EST Elastic CFO sells $924K in common stock - In a regulatory filing, Elastic disclosed that its CFO Janesh Moorjani sold 8.5K shares of common stock on December 9th in a total transaction size of $924K.

17:32 EST American Lithium announces voluntary delisting from Nasdaq - American Lithium Corp. announced that its board has approved the voluntary delisting of its common shares from the Nasdaq Capital Market and the deregistration with the SEC. American Lithium has notified Nasdaq of its intention to voluntarily delist the American Lithium shares. The company currently anticipates that it will file with the SEC on or about December 20, with the delisting of American Lithium Shares taking effect ten calendar days thereafter. As a result, the last trading day of the American Lithium Shares on the Nasdaq Capital Market will be December 27. The American Lithium shares will continue their listing on the TSX Venture Exchange and the Frankfurt Stock Exchange.

17:23 EST Leidos awarded $987M Air Force contract - Leidos was awarded a $987M firm-fixed-price, cost reimbursement, no-fee, cost-plus-fixed-fee, and indefinite-delivery/indefinite-quantity contract for F-16 Foreign Military Sales, or FMS, sustainment support. This contract provides repair and return, engineering and technical services, and analysis and resolution support for diminishing manufacturing sources and material shortages. Work will be performed in Reston, Virginia, and is expected to be completed by May 31, 2034. This contract involves FMS to Taiwan. This contract was a competitive acquisition, and two offers were received. FMS funds in the amount of $1.6M are being obligated at the time of award. The Air Force Life Cycle Management Center is the contracting activity.

17:18 EST Valley National announces retirement of President Thomas Iadanza - Valley National Bancor announced that Thomas A. Iadanza has notified the Company of his intention to retire from his position as President effective June 30. Mr. Iadanza has led a distinguished 45-year career in banking including over the last 13 years at Valley. In his role as President, Mr. Iadanza has helped to lead Valley's growth efforts and evolution to a leading regional bank. Ladanza joined Valley through the 2012 acquisition of State Bancorp, Inc. where he served as Chief Lending Officer. Prior to joining State, Mr. Iadanza held leadership roles at Santander Bank, N.A., Independence Community Bank Corp., Citibank, and European American Bank.

17:08 EST HP Inc. exec Cho sells 40,287 common shares - In a regulatory filing, HP Inc. Personal Systems president Alex Cho disclosed the sale of 40,287 common shares of the company on December 11 at a price of $34.80 per share.

17:03 EST North American Construction awarded contract by copper producer in Australia - North American Construction announced that the MacKellar Group has been awarded an early works and development contract by a major copper producer in the Australian state of New South Wales. The project involves a wide range of production-related activities required for mining but is primarily based on the establishment of site infrastructure in a new mining area, initial overburden removal, and the closure of a previously used reclamation facility. The award of this project, expected to generate approximately $100M in revenue, is from a new customer based in New South Wales, a region that is also new to MacKellar, reflecting our objective of geographic and customer diversification. The project is set to begin in the first quarter of 2025 and completion is scheduled for the second quarter of 2026. The scopes will be completed at an operational long-life copper mine which operates continuously seven days a week, twenty-four hours a day. The heavy and light equipment required for the various work scopes will be sourced from existing owned and leased fleet with the majority of the fleet being equipment that has been transported from Canada. For clarity, the scopes included in this award were contemplated as unsecured work to be completed by existing fleet in the outlook for 2025 provided on December 5. While improving overall visibility and line of sight to now being over 90% of combined revenue midpoint for 2025, this award does not increase the company's estimated ranges for next year.

16:53 EST Rigetti Computing director sells $750K in common stock - In a regulatory filing, Rigetti Computing disclosed that its director Michael Clifton sold 125K shares of common stock on December 10th in a total transaction size of $750K.

16:32 EST ECD Automotive Design announces receipt of Nasdaq delisting notice - ECD Automotive Design an industry leader in delivering restored, modified and electrified Land Rover Defenders, Jaguars, Ford Mustangs, and Toyota FJs, received a notice from The Nasdaq Stock Market notifying the Company that, because the Company is delinquent in filing its Form 10-Q for the quarter ended September 30 the Company no longer complies with Nasdaq Listing Rule 5250(c) which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The Notice provided that the Company shall have 60 calendar days to submit a plan to regain compliance with the Listing Rule, and if Nasdaq accepts the Company's plan, Nasdaq can grant the Company an exception of up to 180 calendar days from the Filing's due date, or until May 19, 2025, to regain compliance with the Listing Rule.

16:31 EST Ares Management expands access to private equity secondaries strategy - Ares Management announced the launch of Ares Private Markets Fund, an Australian-domiciled unit trust designed to provide wholesale clients in Australia access to Ares Private Markets Fund, "APMF". APMF, a U.S.-registered management investment vehicle distributed through Ares' leading Wealth Management Solutions platform, is a private equity investment solution, anchored in secondary investments, that seeks to deliver attractive long-term capital appreciation to investors."

16:27 EST PepsiCo names Christine Tammara as SVP, controller - PepsiCo announced that Christine Tammara has been appointed Senior Vice President and Controller effective May 3, 2025, succeeding Senior Vice President and Controller Marie Gallagher, who previously announced her intention to retire. Tammara will report to PepsiCo CFO Jamie Caulfield.

16:23 EST Copa Holdings: November ASMs up 8.4%, RPMs increased 6.8% vs last year - For November 2024, Copa Holdings' capacity or ASMs increased by 8.4%, while system-wide passenger traffic RPMs increased by 6.8%, compared to 2023. As a result, the system load factor for the month was 86.1%, 1.3% points lower than in November 2023.

16:20 EST Kroger announces new $7.5B share repurchase program - Now that Kroger has terminated the merger agreement, the company is ready to deploy its capacity. With its strengthened balance sheet, Kroger will resume share repurchases after a more than two-year pause. Since announcing the merger, Kroger used its strong free cash flow and debt financing to build meaningful balance sheet capacity while maintaining its investment-grade rating. Kroger's Board of Directors approved a new share repurchase program authorizing the repurchase of up to $7.5B of common stock. The new repurchase authorization replaces Kroger's existing $1B authorization which was approved in September 2022. Kroger intends to enter an accelerated share repurchase agreement for the repurchase of approximately $5B of common stock.

16:18 EST Bristol Myers raises quarterly dividend 3.3% to 62c per share - Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of 62c per share on the 10c par value common stock of the company. The dividend is payable on February 3, 2025, to stockholders of record at the close of business on January 3, 2025. This quarterly dividend represents a 3.3% increase over last year's quarterly rate of 60c per share. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2025 is $2.48 per share. This marks the 16th consecutive year that the company has increased its dividend and the 93rd consecutive year that the company has paid a dividend.

16:17 EST Community Health to sell North Carolina hospital to Duke Health for $280M - Community Health Systems announced that a subsidiary of the company has signed a definitive agreement to sell 123-bed Lake Norman Regional Medical Center in Mooresville, N.C., and related businesses, to Duke Health for approximately $280M, subject to certain net working capital and other adjustments. The transaction is expected to close in the first quarter of 2025, subject to regulatory approvals and closing conditions. The hospital included in this transaction is among the additional potential divestitures discussed on the company's third quarter 2024 earnings call and subsequent public appearances.

16:16 EST Northrop Grumman increases share repurchase program by $3B - Northrop Grumman announced that its board of directors has authorized an additional $3B for the repurchase of the company's common stock, increasing the outstanding authorized amount to approximately $4.2B.

16:15 EST Coca-Cola names Henrique Braun as new COO - The Coca-Cola Company "announced Henrique Braun has been named Executive Vice President and Chief Operating Officer, effective Jan. 1, 2025. In this expanded role, Braun will be responsible for all of the company's operating units worldwide. He will report to Chairman and CEO James Quincey. Braun currently serves as EVP and President, International Development, overseeing the company's operating units for Latin America; Japan & South Korea; ASEAN & South Pacific; Greater China and Mongolia; Africa; India & Southwest Asia; and Eurasia and Middle East."

16:11 EST DBV Technologies announces FDA alignment on Viaskin Peanut patch program pathway - DBV Technologies announced the successful outcome of recent written and oral communication with the FDA that provides a regulatory pathway for the Viaskin Peanut patch program in toddlers 1-3-years-old. The FDA has formalized guidance on an accelerated approval for the Viaskin Peanut patch in toddlers 1-3-years-old. DBV and FDA have agreed on the key design elements for a post-marketing confirmatory study.

16:09 EST Robinhood reports November assets under custody $195B - Robinhood reported select monthly operating data for November. Funded customers at the end of November were 24.8M. Assets under custody at the end of November were $195B. Net Deposits were $5.6B in November. Over the last twelve months, net deposits were $47.4B, translating to an annual growth rate of 50% relative to November 2023 AUC. Equity notional trading volumes were $147.1B. Options contracts traded were 155.5M. Crypto notional trading volumes were $35.2B. Margin balances at the end of November were $6.8B. Total cash sweep balances at the end of November were $26.5B. Total securities lending revenue in November was $23M.

16:07 EST Adobe reports Q4 RPO $19.96B - Reports Q4: Digital Media segment revenue was $4.15 billion, which represents 12 percent year-over-year growth as reported and in constant currency. Document Cloud revenue was $843 million, representing 17 percent year-over-year growth as reported and in constant currency. Creative revenue grew to $3.30 billion, representing 10 percent year-over-year growth or 11 percent in constant currency. Net new Digital Media Annualized Recurring Revenue ("ARR") was $578 million, exiting the quarter with Digital Media ARR of $17.33 billion. Document Cloud ARR grew to $3.48 billion and Creative ARR grew to $13.85 billion. Digital Experience segment revenue was $1.40 billion, representing 10 percent year-over-year growth as reported and in constant currency. Digital Experience subscription revenue was $1.27 billion, representing 13 percent year-over-year growth or 12 percent in constant currency.

16:06 EST AllianceBernstein reports preliminary AUM $813B as of November 30 - AllianceBernstein announced that preliminary assets under management increased to $813B during November from $793B at the end of October. The 2.5% increase in month-end AUM was driven by market appreciation, partially offset by net outflows. By channel, net inflows in Retail and Private Wealth were outweighed by Institutional net outflows.

16:05 EST Microsoft sees $800M charge from GM no longer funding robotaxi

16:01 EST Americas Gold says ISS, Glass Lewis urge holders to vote for all resolutions - Americas Gold and Silver Corporation announced that leading independent proxy advisory firms, Institutional Shareholder Services and Glass Lewis & Co., LLC, have both released reports recommending that Americas shareholders vote in favour of all resolutions in connections with its previously announced proposed acquisition of the remaining 40% interest in the Galena Complex. ISS and Glass Lewis are leading independent corporate governance analysis and proxy advisory firms that provide proxy voting recommendations to institutional shareholders. The independent recommendations of each of ISS and Glass Lewis are intended to assist their shareholder subscribers in making choices regarding proxy voting decisions.

15:25 EST NVR announces $750M share repurchase program - NVR announced that its Board of Directors has authorized the repurchase of up to an aggregate of $750M of its outstanding common stock. The repurchase authorization does not have an expiration date.

14:42 EST Mobileye to use Innoviz LiDARs for Mobileye Drive platform, no terms disclosed - Mobileye (MBLY) and Innoviz Technologies (INVZ) announced earlier on Wednesday that Mobileye will use Innoviz's LiDARs for the Mobileye Drive platform. .."We are pleased to utilize Innoviz LiDARs for the first generation of our Mobileye Drive platform to help enable the autonomous performance of our customers' fleets around the world," said Prof. Amnon Shashua, President and CEO of Mobileye. "The integration of our imaging radars and high-resolution cameras in combination with the Innoviz LiDARs will play a key role in delivering Mobileye Drive as a powerful autonomous driving system that will ultimately create safer, more efficient, and reliable transportation." "This is a proud moment for Innoviz as we progress our relationship with Mobileye," said Omer Keilaf, CEO and Co-Founder of Innoviz Technologies. "Our collaboration on next-generation autonomous vehicle solutions that are both safer and more affordable signifies our shared commitment to accelerate AV adoption. The agreement further attests to Innoviz's capability to meet the stringent requirements of OEMs worldwide and support L4 driving solutions that will help drive a new era of mobility."

14:32 EST Mars Acquisition Corp trading halted, volatility trading pause

13:47 EST North American rail traffic up 2.2% for the week ending December 7 - The Association of American Railroads or AAR reported U.S. rail traffic for the week ending December 7. For this week, total U.S. weekly rail traffic was 520,894 carloads and intermodal units, up 4.4% compared with the same week last year. Total carloads for the week ending December 7 were 224,899 carloads, down 1.8% compared with the same week in 2023, while U.S. weekly intermodal volume was 295,995 containers and trailers, up 9.7% compared to 2023. Five of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included chemicals, up 2,614 carloads, to 33,599; grain, up 2,436 carloads, to 23,143; and miscellaneous carloads, up 1,302 carloads, to 9,318. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 8,665 carloads, to 57,764; motor vehicles and parts, down 2,436 carloads, to 15,046; and nonmetallic minerals, down 892 carloads, to 28,164...North American rail volume for the week ending December 7, on 9 reporting U.S., Canadian and Mexican railroads totaled 331,101 carloads, down 2.6% compared with the same week last year, and 379,058 intermodal units, up 6.8% compared with last year. Total combined weekly rail traffic in North America was 710,159 carloads and intermodal units, up 2.2%. North American rail volume for the first 49 weeks of 2024 was 32,915,088 carloads and intermodal units, up 2.3% compared with 2023. Publicly traded companies in the space include CN (CNI), CSX (CSX), Canadian Pacific Kansas City (CP), Norfolk Southern (NSC), Union Pacific (UNP), Wabtec (WAB),Trinity Industries (TRN),Greenbrier (GBX), FreightCar America (RAIL), and Rail Vision (RVSN). Reference Link

13:20 EST Bank of America sees Q4 wealth management fees up 20% - Sees investment banking fees up 25% y/y. Sees record Q4 for trading.

13:19 EST Comcast Business signs agreement to acquire Nitel, terms not disclosed - Comcast Business has signed an agreement to acquire Nitel, a U.S. managed services provider headquartered in Chicago, from international private equity firm Cinven. The acquisition will expand Comcast Business' presence in connectivity, global secure networking and advanced technology, and enhance Comcast's ability to serve enterprise clients. Nitel is a network-as-a-service provider, specializing in delivering advanced managed services and connectivity solutions to enterprise customers across the U.S. With a focus on high-performance networking, cloud services, and cybersecurity, Nitel empowers businesses to optimize their operations and drive digital transformation. Known for its customer-centric approach, Nitel offers customized solutions that meet the unique needs of its clients, enabling them to stay competitive in a rapidly evolving digital landscape. Nitel has deep expertise providing integrated managed network and security solutions to its 6,600 clients across the country, with a strong focus on mid-size enterprise clients, including those in financial services, healthcare, and education. Adding Nitel's comprehensive solutions and specialized cloud-based services to Comcast Business' advanced connectivity portfolio will provide further growth opportunities. It will also enable customers to seamlessly manage their operations and networks securely and more efficiently. Comcast Business' acquisition of Nitel is subject to regulatory approvals and other customary closing conditions. As a result of the transaction, international private equity firm Cinven will sell its stake in Nitel. Financial terms of the acquisition were not disclosed.

12:54 EST Microsoft working to bring all PC games with Xbox features into Xbox app - Microsoft said in a blog post that the new PC gaming Home experience it has been testing with Xbox Insiders is now available in the Xbox app on Windows PC for all players. "Home highlights featured content so players can stay up to date on game releases, new events, Game Pass content, sales, and more," said Chris Charla, general manager of content curation and programs at Xbox. "There are also new curated collections and recommendations, deals and discounts, and the Jump back in feature, which enables players in Compact Mode to click on any game card and jump right back into gameplay from the game's hub. While many players use the app to find and launch awesome titles from Game Pass, the Xbox app is also becoming a great way for players to find cool Xbox games that aren't available with Game Pass. Earlier this summer, we began working with partners to bring all PC games with Xbox features into the Xbox app. We're super excited to see what Xbox games come to Windows PC from game creators in the future and to welcome nearly 400 titles that previously weren't discoverable or purchasable in the Xbox app. Among this list are dozens of games from veteran Japanese studios Kemco and Kairosoft, as well as games such as Shovel Knight Treasure Trove by Yacht Club the Jackbox Party Pack, The Invincible by Double 11 and many, many more." Reference Link

12:17 EST The Hartford expands partnership with Workday for wellness - The Hartford (HIG) is enhancing its relationship with Workday (WDAY) by becoming a strategic Workday Wellness partner. Workday Wellness, an AI-powered solution, will be designed to connect employers and employees to top wellness partners, offering a highly personalized experience that reduces costs and administration hours. Leveraging Illuminate and Workday Peakon Employee Voice, it will provide companies with real-time insights into which benefits and wellness offerings their employees want and use so they can improve programs and seamlessly add new offerings.

12:02 EST Nokia selected by Nscale for IP network at data center - Nokia said it has been selected by Nscale to deliver an IP network solution to support artificial intelligence workloads at Nscale's new data center in Stavanger, Norway. The data center will enable cutting-edge AI services, including graphics processing unit as a service, the company said in a statement.

12:00 EST D-Wave Quantum falls -12.2% - D-Wave Quantum is down -12.2%, or -57c to $4.11.

12:00 EST Figs rises 16.5% - Figs is up 16.5%, or 84c to $5.97.

12:00 EST Skillsoft rises 21.1% - Skillsoft is up 21.1%, or $3.10 to $17.82.

11:45 EST Archer Daniels board extends share repurchase program - ADM announced that its board of directors authorized an extension of ADM's share repurchase program. "The original 5-year program authorized the purchase of 100,000,000 shares of ADM stock in between Jan. 1, 2015, and Dec. 31, 2019. In 2019, the program was extended through Dec. 31, 2024 and increased to 200,000,000 shares. The program has now been extended an additional five years, and the Board also authorized repurchases of up to an additional 100,000,000 shares under the extended program. The share repurchase program now authorizes the purchase of 300,000,000 shares through Dec. 31, 2029," the company stated.

11:30 EST Frequency Electronics CEO sees 'huge' potential in small satellites - On the company's Q2 earnings call, Frequency Electronics President and CEO Tom McClelland stated, according to a transcript of the event: "We are seeing a lot more, more and more new business in the proliferated small satellite domain. It's very clear that this is the direction in which space technology is headed. At this time, less than 10% of our backlog is associated with proliferated small satellites, but it's anticipated that this will grow dramatically over the next decade. The potential is huge."

11:13 EST Miami Dolphins announce sale of limited interest to Ares Management - The NFL's Miami Dolphins and Chairman of the Board Stephen Ross have announced a strategic investment by Ares Management funds and Brooklyn Nets owners Joe Tsai and Oliver Weisberg. "In addition to the Miami Dolphins, the transaction includes iconic assets such as Hard Rock Stadium and the Formula 1 Crypto.com Miami Grand Prix, with the investment fueling continued growth across Ross' diverse South Florida-based sports and entertainment portfolio. Ares will acquire a 10% stake, while Tsai and Weisberg together will hold a 3% interest, pending final closing of the agreements. The minority, non-controlling interest sale was approved by the NFL at the league meeting on Wednesday, December 11," the team announced. "The Miami Dolphins represent an iconic franchise with a deeply engaged fanbase, and Ares is honored to invest alongside Joe and Ollie to support the team's long-term strategic goals. Moreover, Steve has been the architect of an impressive ecosystem of sports, entertainment and real estate assets that underscores the sector's significant potential for growth and value creation to the benefit of fans, local communities and financial stakeholders. We look forward to working with Steve to continue unlocking new and exciting opportunities ahead," said Mark Affolter and Jim Miller, Co-Heads Sports, Media & Entertainment at Ares. Reference Link

10:55 EST Google unveils latest AI model Gemini 2.0 - Google has released the first version of the company's Gemini 2.0 family of artificial intelligence models, said to be twice as fast as the previous version and expected to power virtual agents assisting users. "Today, we are announcing Gemini 2.0 Flash Experimental to enable even more immersive and interactive applications, as well as new coding agents that will enhance workflows by taking action on behalf of the developer," Google said. Flash 2.0 is twice as fast as 1.5 Pro while achieving stronger performance, includes new multimodal outputs, and comes with native tool use. Google is also introducing a Multimodal Live API for building dynamic applications with real-time audio and video streaming. Starting today, developers can test and explore Gemini 2.0 Flash via the Gemini API in Google AI Studio and Vertex AI during its experimental phase, with general availability coming early next year. Reference Link

10:35 EST Kroger responds to Albertsons' 'baseless' lawsuit - The Kroger Co. (KR) issued the following statement: "Albertsons' (ACI) claims are baseless and without merit. Kroger refutes these allegations in the strongest possible terms, especially in light of Albertsons' repeated intentional material breaches and interference throughout the merger process, which we will prove in court. This is clearly an attempt to deflect responsibility following Kroger's written notification of Albertsons' multiple breaches of the agreement, and to seek payment of the merger's break fee, to which they are not entitled. Kroger looks forward to responding to these baseless claims in court. We went to extraordinary lengths to uphold the merger agreement throughout the entirety of the regulatory process and the facts will make that abundantly clear. We are incredibly proud of the Kroger team for how they worked through the merger process with the highest degree of integrity and commitment. We are confident in Kroger's value creation model to drive sustainable growth. Kroger's Board of Directors is currently evaluating next steps that serve the best interests of Kroger's customers and associates, and create value for shareholders."

10:22 EST AstraZeneca says 87.5% of Lynparza-treated patients alive at six years in trial - Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck's (MRK) Lynparza demonstrated sustained, clinically meaningful improvements in overall survival, invasive disease-free survival and distant disease-free survival at six years for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer, AstraZeneca announed. These results were presented at the San Antonio Breast Cancer Symposium 2024 and "build on the positive primary results published in The New England Journal of Medicine," the company added. At a median follow-up of 6.1 years in eligible patients, who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy, results showed Lynparza reduced the risk of death by 28% versus placebo. In addition, 87.5% of patients treated with LYNPARZA remained alive versus 83.2% of those on placebo.

10:13 EST TD Bank insider arrested, charged with facilitating money laundering - A former Florida-based employee of TD Bank N.A. was arrested and charged by criminal complaint yesterday for facilitating money laundering to Colombia through the financial institution. According to court documents, Leonardo Ayala worked at a TD Bank store in Doral, Florida, between February and November 2023. Starting in June 2023, Ayala allegedly exploited his position as a bank employee to facilitate money laundering. As alleged, after another TD Bank employee opened accounts in the names of shell companies with nominee owners, Ayala assisted the money laundering network by issuing dozens of debit cards for the accounts in exchange for bribes. Those accounts were then allegedly used to launder millions of dollars in narcotics proceeds through cash withdrawals at ATMs in Colombia. Ayala is charged with one count of conspiracy to commit money laundering. If convicted, he faces a maximum penalty of 20 years in prison. A federal district court judge will determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors. Reference Link

10:06 EST Quantum Corp trading halted, volatility trading pause

10:00 EST C3 AI falls -10.5% - C3 AI is down -10.5%, or -$4.38 to $37.35.

10:00 EST Bausch + Lomb falls -11.8% - Bausch + Lomb is down -11.8%, or -$2.44 to $18.21.

10:00 EST REV Group rises 14.2% - REV Group is up 14.2%, or $4.19 to $33.79.

09:51 EST LiveOne signs multiyear deals with BMI, ASCAP, restructures $8M in payables - LiveOne announced certain balance sheet restructuring initiatives and strategic partnerships update, including multiyear deals with BMI and ASCAP and the restructuring of $8M in payables. The company said the partnerships boost management's ability to close 65+ B2B deals in the pipeline.

09:48 EST REV Group rises 10.9% - REV Group is up 10.9%, or $3.24 to $32.84.

09:48 EST ADC Therapeutics falls -8.9% - ADC Therapeutics is down -8.9%, or -31c to $3.17.

09:47 EST Bausch + Lomb falls -12.7% - Bausch + Lomb is down -12.7%, or -$2.62 to $18.03.

09:45 EST ReNew Energy Global receives acquisition proposal for $7.07 per share in cash - ReNew Energy Global has received a non-binding proposal dated December 10, 2024 from Abu Dhabi Future Energy Company PJSC-Masdar, Canada Pension Plan Investment Board, Platinum Hawk C 2019 RSC Limited as trustee for the Platinum Cactus A 2019 Trust and Sumant Sinha to acquire the entire issued and to be issued share capital of the Company not already owned by members of the Consortium, for cash consideration of $7.07 per share. The ReNew Board of Directors have formed a Special Committee led by Manoj Singh, the Lead Independent Director, consisting of the six independent non-executive ReNew Directors to consider the non-binding proposal. The role of the Special Committee is to constructively explore and evaluate all strategic capitalization / financing opportunities available to the Company, including the proposal received from the Consortium, and act in the interests of all investors. To assist in these efforts, the Special Committee has retained an independent financial advisor, Rothschild & Co and independent legal counsel, Linklaters. While the Special Committee's evaluations are underway, the ReNew Executive Management's primary focus will be to continue to ensure the effective management of the Company and in addition, contribute to the evaluation process, as required by the Special Committee.

09:35 EST NEHC Stock trading halted, volatility trading pause

09:27 EST NeuroSense concludes Type C meeting with FDA for PrimeC treatment - NeuroSense Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral sclerosis, or ALS. The purpose of the meeting was to discuss the design of a proposed Phase 3 clinical study and the plan for submission of an eventual 505 marketing application. The Company had a productive discussion with the FDA regarding the design of the planned Phase 3 pivotal study with PrimeC, including efficacy and safety measurements. The FDA's positive feedback and guidance on overall trial design marks a noteworthy achievement for NeuroSense, as alignment on the design is a critical step in enabling the study to meet regulatory expectations and potentially provide sufficient data for the drug's approval. In light of the FDA's feedback, NeuroSense plans to submit a final protocol to the FDA during the first half of 2025 with the aim of commencing enrollment of the pivotal Phase 3 study in mid-2025, which would include approximately 300 patients divided by a ratio of 2:1, PrimeC to placebo. The Phase 3 study is expected to be a randomized, multi-center, multinational, prospective, double-blind, placebo-controlled study, with an open label extension, to evaluate the efficacy and safety of PrimeC in people living with ALS. Following 12 months of treatment, it is expected that all participants will transition to PrimeC for a 12-month OLE.

09:26 EST Founder Group partners with VC AI to co-develop UAV for solar farm inspections - Founder Group announced its strategic partnership with VC AIto co-develop advanced AI-powered Unmanned Aerial Vehicle for solar farm inspections, ensuring the optimal performance of solar farms. Beyond standard terrain mapping capabilities, thermal imaging cameras, and lightweight construction, the UAVs incorporate VC.AI's proprietary generative AI software and advanced deep learning algorithms. These technologies enable the UAVs to autonomously identify anomalies and detect defects or malfunctions in the solar panels during inspections, eliminating the need for human intervention. This significantly enhances the efficiency of solar farm inspections compared to traditional manual methods. By deploying AI-powered UAVs on both FGL's own solar farms and those of its clients, the company improves operational efficiency and optimizes its solar operations and maintenance processes.

09:19 EST VEON notes launch of open-source Kazakh-language large language model - VEON noted the launch of an open-source Kazakh-language large language model, developed by a consortium coordinated by the Ministry of Digital, Innovations, and Aerospace Industry of the Republic of Kazakhstan. The development of Kaz-LLM was led by the Institute of Smart Systems and Artificial Intelligence at the Nazarbayev University of Kazakhstan, in partnership with VEON's QazCode, Beeline Kazakhstan and the Astana Hub. With over 150 billion tokens collected, curated, synthesized and translated, the Kaz-LLM is capable of interacting in Kazakh language as well as in Turkish, English and Russian. With an 8 billion and a 70 billion parameter versions, the Kaz-LLM, developed in Kazakhstan, will help accelerate the creation and adoption of AI-powered products and services in the country. The model has been published on the Hugging Face platform for developers, ahead of its full launch. The initiative, in which VEON's QazCode is the only private sector partner, aligns closely with VEON's mission to provide speakers of low-resource languages with augmented intelligence tools to enhance their daily lives, starting with Kazakhstan, VEON's most advanced market in terms of augmented intelligence capabilities.

09:17 EST PlayAGS announces expiration of HSR Act waiting period for acquisition - PlayAGS announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with the previously announced agreement for the Company to be acquired by affiliates of Brightstar Capital Partners for $12.50 per share in cash, The HSR Act waiting period expired at 11:59 p.m., Eastern Time, on December 9, 2024, satisfying an important condition necessary for the completion of the Proposed Transaction, which is expected to close in the second half of 2025, subject to other conditions and regulatory approvals.

09:15 EST Know Labs announces NYSE /American acceptance of plan for regaining compliance - Know Labs announced that on December 10 it received notification rom the NYSE American that the Company's previously-submitted plan to regain compliance with the NYSE American's listing standards was accepted. In the Acceptance Letter, NYSE American granted the Company until March 27 , to regain compliance with the continued listing standards.

09:12 EST Ro, Eli Lilly to streamline patient access to Zepbound single-dose vials - Ro announced earlier that it is working with Eli Lilly and Company to streamline access to Zepbound single-dose vials for Ro patients with obesity. The vials will be available as a treatment option with an on-label prescription from a Ro-affiliated provider via an integration with the LillyDirect self-pay pharmacy channel. This offering will make it easier for Ro's clinically eligible patients to get the FDA-approved, rigorously tested Lilly medicine delivered directly to them at the self-pay price, the company said in a statement. "Offering Zepbound single-dose vials - the most affordable branded incretin medicine by list price - through another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. "Our goal is to break down barriers and provide patients with safe and effective options they can rely on."

09:08 EST Globant and Faros AI team to support 'agentic AI-based projects' - Faros AI announced a strategic partnership with Globant This collaboration aims to accelerate client transformation through faster and more efficient Agentic artificial intelligence projects, providing a unified platform that highlights the capabilities and benefits of AI-empowered teams. Faros AI optimizes engineering workflows by benchmarking productivity across the software development lifecycle SDLC and identifying bottlenecks, hotspots, and opportunities for improvement. Globant will empower its engineering teams globally with this new tool so that Globers can make faster and more confident decisions for software development. The expected boost in developer productivity, software quality, and system reliability will improve client satisfaction and help win new opportunities. "We are transforming our approach to team performance by leveraging AI to maximize the strengths of both technology capability and human authenticity," said Diego Tartara, Chief Technology Officer at Globant. "Globant's partnership with an innovator like Faros AI represents a natural and essential step forward in helping organizations capitalize on AI breakthroughs at enterprise scale. Data-driven insights into our engineering processes will empower us to deliver greater value to our clients faster and more efficiently."

09:03 EST Provectus announces the launch of VisiRose - Provectus Biopharmaceuticals announced the launch of VisiRose, Provectus's first Founded Entity. This new clinical-stage biotechnology company is focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy, RB PDAT, for the treatment of infectious keratitis and other serious eye infections using Provectus's bioactive synthetic small molecule and active pharmaceutical ingredient, API, Rose Bengal Sodium, RBS. Dominic Rodrigues, Acting Chief Executive Officer of VisiRose, who is also President and Vice Chairman of the Board of Directors of Provectus, said, "RB PDAT represents a consequential solution for patients at risk of vision loss from infectious keratitis. We believe this innovative therapy combines precise infection-fighting capabilities with vision-preserving benefits, paving the way for a brighter future for those struggling with this challenging condition."

09:03 EST C3 AI and RTX expand joint intiatives - C3 AI (AI) and Collins Aerospace, an RTX (RTX) business, announced expanded joint initiatives to develop and deliver AI solutions across the defense and intelligence space.

09:02 EST Hilton, Grubhub Onsite expand partnership - Grubhub Onsite and Hilton are expanding their partnership by bringing on-demand food, grocery, and convenience item delivery to over 2,600 hotels across the Hampton by Hilton, Tru by Hilton, and Spark by Hilton brands. This expansion means more guests can now enjoy seamless access to Grubhub's extensive Marketplace of more than 375,000 merchants by simply scanning a QR code, offering the ultimate convenience during their stay. Guests can also enjoy one free month of Grubhub+ for perks like $0 delivery fees and lower service fees on eligible orders, and 5% credit back on pickup orders, making it even easier for guests to get the items they need.

09:01 EST Arthur J. Gallagher acquires Sheila J. Butler & Company for undisclosed amount - Arthur J. Gallagher & Co. announced the acquisition of Carrollton, Georgia-based Sheila J. Butler & Company,or SJB. Terms of the transaction were not disclosed. SJB is an employee benefits brokerage firm serving groups of all sizes in western Georgia, including greater Atlanta. Sheila J. Butler, Blake Butler and their team will remain in their current location under the direction of Colby Paxton, head of Gallagher's Southeast region employee benefits consulting operations.

09:00 EST Vizsla Silver begins test mining at Panuco silver-gold project - Vizsla Silver announced the commencement of its fully funded and fully permitted test mining and bulk sample program at its flagship, 100%-owned Panuco silver-gold project, located in Sinaloa, Mexico. The primary objectives for the Program will be to reconcile actual geotechnical conditions at Copala with the current geotechnical model in preparation for full-scale development & operations, provide initial reconciliation of resource models against actual grades and tonnes, and build operational experience for the Panuco team. Program highlights include: Comprehensive Test Mining: Focused on underground ramp development, lateral access, and ore extraction from the 460-level zone on the Copala structure; Bulk Sampling: Approximately 10,000 tonnes of high grade material is planned to be mined as part of the development. This material will be stockpiled on site and may be used for future metallurgical testing; Surface Infrastructure Development: Includes construction of portal facilities, access roads, and laydown areas, supporting efficient test mining operations. The test mining program at Panuco, is focused on key areas of underground development and surface infrastructure designed to support the ultimate extraction and processing of bulk mineralization from Copala. The underground scope includes approximately 1,071 meters of ramp and lateral development, with 169 meters dedicated to ore development. Mining methods include portal and ramp preparation as well as ore development tunnels, designed for safe and efficient bulk sampling. The underground mining contract was awarded on 5 December and the contractor is currently mobilising to site with the first personnel arriving on 9 December. Both the earthworks and mining contracts have been awarded to well established Mexican contractors. In addition to the test mining and bulk sample program, Vizsla continues its ongoing exploration efforts in the eastern portion of the district with two drill rigs. The fully funded 10,000 metre discovery-based drill campaign is focused on locating new centres of high-grade mineralization outboard of the current PEA mine plan. Moreover, the Company has just awarded a contract to Geofisica TMC to conduct a ground HLEM survey on six selected areas within Panuco project to further enhance the possibilities of finding new mineralization.

09:00 EST AnaptysBio trading resumes

08:55 EST Thumzup launches on Elon Musk's X, expands service offerings across verticals - Thumzup Media has announced the official integration of its platform with Elon Musk's X Corp formerly Twitter . This milestone grants Thumzup advertisers access to X's impressive base of 535M monthly active users , positioning the Company as a disruptive force in digital advertising..."Our launch on X Corp signifies a quantum leap in Thumzup's mission to revolutionize advertising," said Robert Steele, CEO of Thumzup. "By merging our innovative tools with X's massive audience, we believe we can deliver strong opportunities for brands to scale their visibility and engagement at new levels."

08:46 EST Alpha Cognition: Data support ALPHA-1062 develpment for militaryTBI treatment - Alpha Cognition announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury or mTBI. The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury...This second pre-clinical study in a rodent model, supported by the US Department of Defense DOD, is a collaboration with investigators at the Seattle Institute of Biomedical and Clinical Research The study is ongoing, with interim data demonstrating that ALPHA-1062 administration following 3 consecutive days of blast induced mTBI, results in a reduction of TBI associated neuropathology. Key findings demonstrated that, ALPHA-1062 administration reduced levels of neuroinflammation markers and neuropathology that occurs after blast trauma. High dose ALPHA-1062 reduced the levels of myeloid cell activation or CD 68 across multiple brain regions one month after blast. High dose ALPHA-1062 also demonstrated the ability to reduce midbrain astrogliosis GFAP . The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury," said Denis Kay, ACI's Chief Scientific Officer. Further analysis of neuropathology and neurobehavioral [functional recovery] data is ongoing with the final study report due Q2/2025.

08:44 EST United States Antimony announces corporate headquarters move - United States Antimony announced the decision by its Board of Directors to move its corporate headquarters to Dallas, Texas, from Thompson Falls, Montana. While the Company's primary producing assets are located in Montana, none of the executives or board members reside there. There will be no expenses incurred associated with this transition.

08:42 EST New Fortress Energy executes 10 year charter for Energos Eskimo, no terms - New Fortress Energy has executed a 10 year charter agreement for the Energos Eskimo, a 160,000 m3 floating storage and regasification unit, with the Egyptian Natural Gas Holding Company or EGAS . The Eskimo will be deployed to EGAS' LNG import terminal located at Ain Sokhna, Egypt and is expected to begin operations in the summer of 2025.

08:40 EST Foremost CEO: 'Well on way' to realizing 'ambitious goals' in Athabasca Basin - Foremost Clean Energy issued a letter to shareholders from its President and CEO Jason Barnard, which read in part, "As we end 2024, I wanted to take a moment to reflect on our Company's achievements over the past year and set out our objectives for the upcoming year and beyond. 2024 has truly been an evolutionary year for Foremost, marked by a series of strategic business developments and key advancements in our asset portfolio. Over the course of the last 12 months, we have successfully negotiated an option agreement with Denison Mines Corp. (DNN) for 10 prospective uranium properties significantly enhancing our position in the mining sector. Our commitment to growth is further demonstrated through the completion of drill programs at our Zoro Lithium Property and the Hatchet Lake Uranium Property. Additionally, we are excited about the planned spin-out of the Company's Winston Gold/Silver Project into Rio Grande Resources. Bolstered by our success in securing over C$13.5 million in gross proceeds through two equity financing rounds, it is evident that Foremost is methodically positioning itself for future growth. And in a strong show of confidence in the Company's future, I am pleased to report that insiders have united to invest more than C$2.4 million in share purchases over the past year. As a fellow investor and shareholder, I completely understand and share the disappointment associated with the apparent disconnect between Foremost's operational performance and its share price. However, I firmly believe that we are on the brink of what will become our most transformative year yet. I am filled with eagerness as we kickstart our efforts committing $6.5 million dollars in exploration in 2025 on several of the Uranium Properties which are drill-ready and/or drill-permitted, each showcasing incredible potential. Our strong foundational elements, coupled with strategic partnerships and an expanding market presence, suggest that our Company could be poised for significant growth...Energy needs are projected to surge, bolstered by global energy policies aimed at carbon reduction, generative A.I. power needs, declining supply and heightened geopolitical tensions. We are entering an extremely exciting time in what looks like a sustained uranium bull market. As demand for nuclear energy surges, so too does the need for uranium, which will inevitably drive exploration and generate greater market interest...Foremost is dedicated to unlocking the immense potential of its underexplored land package in the Athabasca Basin, driven by a mission to make significant discoveries through active exploration. By employing a systematic and scientific approach in our exploration activities, we establish a framework that effectively prioritizes our efforts and directs our attention toward the most promising targets from the outset. As Foremost commences its exploration efforts on the Uranium Properties, we are determined to emerge as a preeminent player in the Athabasca uranium exploration sector. With a clear vision and robust exploration strategy, we are well on the way to realizing our ambitious goals in one of the most prolific uranium districts in the world. The new collaboration with Denison, a leading C$2.8 billion uranium miner and developer, provides Foremost unparalleled technical, operational, and financial support, enhancing its capacity for exploration success. Denison's evaluation and decision to engage with Foremost is a meaningful validation of the Company's business model. By fostering our relationship and key collaborations, we aim to maximize shareholder value and achieve long-term success."

08:39 EST La Rosa Holdings launches its first office in North Carolina - La Rosa Holdings announced the opening of its first office in North Carolina. North Carolina continues to demonstrate significant momentum in its real estate market. As of October 2024: Home prices in North Carolina increased by 2.5% year-over-year, reflecting sustained demand and market strength. On average the number of homes sold rose by 4.6%, showcasing growing buyer activity despite higher interest rates. The inventory of homes for sale grew by 19.0%, signaling increased opportunities for buyers.

08:37 EST Albertsons announces $2B share repurchase program - The board of directors has also authorized a share repurchase program of up to $2B, inclusive of the existing authorization. The company's share repurchase program could include open market repurchases, accelerated share repurchase programs, tender offers, block trades, potential privately-negotiated transactions, or trading plans intended to comply with the federal securities laws. The company's dividend increase, and share repurchase program are expected to be funded with cash generated from operations.

08:37 EST Albertsons to increase quarterly dividend 25% to 15c per share - The company announced that its board of directors intends to increase its quarterly cash dividend 25% from 12c per share to 15c per share, which the company expects to take effect beginning with the next quarterly dividend declaration.

08:35 EST Cerberus says 'no intention of selling any' of its Albertsons shares - Cerberus Capital Management, Albertsons' largest shareholder, stated that, "While we are disappointed with the courts' decisions, we remain confident in Albertsons' strength as a standalone company, and we believe that it is significantly undervalued in its current trading range. Accordingly, Cerberus has no intention of selling any of its shares in the Company. Cerberus initially invested in Albertsons in 2006, with additional investments in 2013 and 2015 to support significant and strategic value creation opportunities. As a long-term investor in and partner to Albertsons across multiple investments and throughout the evolution of its competitive environment, Cerberus is proud of the Company's performance and it will continue to be a strong supporter of Albertsons, its talented leadership team, and its dedicated associates."

08:35 EST IDT Corp's BOSS Money announces zero-fee money transfers for the holidays - BOSS Money announced new holiday deals that make sending money to family and friends in Mexico and around the world more affordable than ever before. New BOSS Money customers can celebrate the holiday with five Zero-Fee transfers to Mexico and two Zero-Fee transfers to all other Boss Money destination countries when sending from their debit card or bank account on the BOSS Money and BOSS Revolution Calling apps. Existing BOSS Money customers will receive a special BOSS Money Holiday Promo Code for two Zero-Fee transfers between December 20th and 25th. BOSS Money also announced expanded payout options, providing more ways to share the joy: Customers sending to the Dominican Republic, Guatemala, Honduras, Jamaica, and the Philippines can send cash directly to their recipient's bank-issued debit card; Customers sending to Mexico and Peru can now use the BOSS Money app to transfer cash to mobile wallets. In Mexico: Bankaya, Mercado Pago, Spin by Oxxo and Techreo. In Peru: Yape.

08:34 EST AmpliTech Group announces development, deployment of HEMT amplifiers - AmpliTech Group announces the development and deployment of its proprietary low-noise cryogenic High Electron Mobility Transistor amplifiers. These amplifiers play a critical role in enabling quantum computers to operate efficiently at extremely low temperatures of 4 Kelvin, a prerequisite for high-fidelity quantum operations. AmpliTech has demonstrated its technological leadership by delivering working units of its cryogenic Low-Noise Amplifiers to two Fortune 50 companies at the forefront of the quantum computing sector. AmpliTech has also delivered units to Universities and Research institutions in this rapidly emerging technology sector. This milestone solidifies AmpliTech as the high-performance U.S.-based manufacturer of cryogenic LNAs, optimized for quantum computing at 4K temperatures, ensuring reliability and precision for the most advanced quantum applications. The operation of these LNAs at almost absolute zero temperatures is a very special technology that AmpliTech has developed for this rapidly growing industry. The Company has been keenly monitoring this revolutionary industry sector for years and has been working closely with industry leaders to develop viable solutions to power next-generation quantum technology.

08:33 EST T. Rowe Price reports preliminary AUM $1.67T as of November 30 - T. Rowe Price Group reported preliminary month-end assets under management of $1.67T as of November 30. Preliminary net outflows for November were $6.4B, which includes a portion of the previously disclosed subadvisory redemption.

08:32 EST Match Group initiates dividend of 19c per share, announces $1.5B share buyback - Match Group will host its inaugural Investor Day, with executives outlining the company's strategic priorities and vision for the future, along with its medium-term financial outlook, capital allocation priorities, and total shareholder return algorithm. In conjunction with Investor Day, the company announced initiatives to return capital to shareholders, including initiation of a cash dividend program and a new $1.5B share buyback authorization. The company announced its Board of Directors has declared a cash dividend of 19c per share of outstanding common stock, payable on January 21, 2025 to shareholders of record as of the close of business on January 6, 2025. The Board of Directors also authorized the repurchase of up to an additional $1.5B in aggregate value of shares of Match Group common stock, which will take effect when the existing share repurchase authorization, of which $247M in aggregate value of shares of Match Group common stock remains available, is exhausted.

08:31 EST Pedevco appoints J. Douglas Schick as CEO, Jody Crook as CCO - PEDEVCO announced that its Board of Directors has appointed J. Douglas Schick, the Company's current President since August 2018, as the Company's new CEO and a member of the Board, and is expanding its executive management and development team with the hiring of Mr. Jody Crook as the Company's new CCEI, all effective January 1, 2025. Mr. Schick succeeds Dr. Simon G. Kukes, who will step down as CEO and assume the role of Executive Chairman of the Company's Board of Directors. Crook has served as a Senior Advisor for Land and Business Development activities for the Company since April 2020.

08:27 EST Stingray Advertising expands retail media network - Stingray announced the expansion of its retail media network with the introduction of video advertising across METRO food and pharmacy banners. This new offering enhances the existing in-store audio advertising partnership, providing brands with a dynamic platform to engage and convert shoppers through digital signage. Advertisers have the flexibility to use either existing creative or choose from Stingray Advertising's six animated templates which are designed to be conducive to a physical retail environment while complimenting the shopper's in-store experience: aisle driver, brand driver, co-branded driver, direct response, recipe driver, and web driver. Additionally, Stingray Advertising has teamed up with Vistar Media for all delivery of video advertising inventory across the METRO retail network. By leveraging Vistar's advanced technology platform, Stingray Advertising can efficiently manage and optimize all in-store video advertising campaigns directly while also offering programmatic deal types, such as PMPs.

08:26 EST Eli Lilly announces results from EMBER-3 study of imlunestrant - Eli Lilly announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, or SERD, in patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative, or HER2-, advanced breast cancer, or ABC, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival as monotherapy in patients with an ESR1 mutation versus standard of care endocrine therapy, reducing the risk of disease progression or death by 38%. Imlunestrant in combination with Verzenio reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients. These results were published in The New England Journal of Medicine and will be shared in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium, or SABCS, Wednesday, December 11 at 9:15 AM CT/10:15 AM ET. These data are being submitted to regulatory health authorities globally. In the EMBER-3 study, patients were randomized 1:1:1 to receive imlunestrant alone, SOC ET, or the imlunestrant-abemaciclib combination. Randomization was stratified by prior CDK4/6 inhibitor use, the presence of visceral metastases and geographic region. Patients enrolled as first line treatment for ABC, following disease recurrence on or within 12 months of completing adjuvant AI, with or without CDK4/6 inhibitor for early breast cancer, or as second line treatment for ABC, following progression on AI, with or without CDK4/6 inhibitor as initial therapy for ABC. Primary endpoints were investigator-assessed PFS of imlunestrant versus SOC ET therapy in patients with ESR1 mutations, imlunestrant versus SOC ET in all patients, and imlunestrant-abemaciclib versus imlunestrant in all patients. Imlunestrant significantly improved PFS versus SOC ET in patients with an ESR1 mutation. In patients with an ESR1 mutation, median PFS was 5.5 months with imlunestrant versus 3.8 months with SOC ET. The overall response rate with imlunestrant was 14% compared to 8% with SOC ET in patients with an ESR1 mutation. In all patients, the median PFS was 5.6 months with imlunestrant versus 5.5 months with SOC ET and did not reach statistical significance. Consistent with preclinical data demonstrating central nervous system penetrance and CNS-activity of imlunestrant, CNS progression rates from a post-hoc analysis were lower with imlunestrant in all patients, as well as patients with an ESR1 mutation, however, these analyses are limited by low event numbers and lack of mandated serial asymptomatic CNS imaging in all patients. Imlunestrant significantly improved PFS versus SOC ET in patients with an ESR1 mutation. In patients with an ESR1 mutation, median PFS was 5.5 months with imlunestrant versus 3.8 months with SOC ET. The overall response rate with imlunestrant was 14% compared to 8% with SOC ET in patients with an ESR1 mutation. In all patients, the median PFS was 5.6 months with imlunestrant versus 5.5 months with SOC ET and did not reach statistical significance. Consistent with preclinical data demonstrating central nervous system penetrance and CNS-activity of imlunestrant, CNS progression rates from a post-hoc analysis were lower with imlunestrant in all patients, as well as patients with an ESR1 mutation, however, these analyses are limited by low event numbers and lack of mandated serial asymptomatic CNS imaging in all patients. Imlunestrant-abemaciclib significantly improved PFS compared to imlunestrant in all patients, regardless of ESR1 mutation status, with median PFS of 9.4 months for imlunestrant-abemaciclib versus 5.5 months for imlunestrant alone. The PFS benefit of the combination was consistent across subgroups, regardless of ESR1 mutation, or PI3K pathway mutation status, and including in patients who had previously received CDK4/6 inhibitor treatment. In all patients, the ORR with imlunestrant-abemaciclib was 27% compared to 12% with imlunestrant alone. Safety in the imlunestrant-abemaciclib arm was consistent with the known safety profile of fulvestrant in combination with abemaciclib, with mostly low-grade adverse events including diarrhea, nausea, neutropenia and anemia and had a low discontinuation rate. Overall survival results for EMBER-3 were immature at the time of analysis. The trial will continue to assess OS as a secondary endpoint. An estimated 70% to 80% of hormone receptor positive breast cancers are ER+ and after progression on initial endocrine therapy, are predominantly treated with fulvestrant, which is administered by intramuscular injection in a doctor's office. According to patient-reported outcomes data from EMBER-3, 72% of patients receiving fulvestrant in the standard ET group reported injection site pain, swelling, or redness. Imlunestrant is an orally administered, brain penetrant, pure ER antagonist that delivers continuous ER target inhibition. Imlunestrant is also being investigated in the adjuvant setting in people with ER+, HER2- early breast cancer with an increased risk of recurrence. This Phase 3 trial, EMBER-4, is expected to enroll 6,000 EBC patients worldwide.

08:25 EST AnaptysBio trading halted, news pending

08:24 EST Parex Resources announces enhanced partnership with Ecopetrol - Parex Resources (PARXF) and its strategic partner Ecopetrol (EC) announce that they have executed agreements whereby Parex will earn a 50% working interest in four blocks located in the Putumayo Basin of Colombia as well as the Farallones Block in the Llanos Foothills of Colombia. Additionally, the Company provides an operational update and reports that it is abandoning the Arantes exploration well at LLA-122. Key Highlights: Executed Putumayo business collaboration agreements to establish a new core area for Parex, where over 350 million barrels of oil have been recovered to date through primary recovery methods with limited recent drilling. The Putumayo Blocks offer significant upside potential and the ability to meaningfully improve recovery factors through the application of lower-risk infill drilling, re-completions, facility upgrades, and enhanced oil recovery implementation. Parex's independent qualified reserve evaluator, GLJ, has recognized Company interest proved plus probable reserves of 18 million barrels. Parex will assume operatorship in all future drilling and capital activities; Ecopetrol will retain operatorship of current and future production. Extended Llanos Foothills position through the addition of a top-ranked exploration target on the Farallones Block. November 2024 average production was 44,700 boe/d; the Company expects to achieve its FY 2024 average production guidance of 49,000 to 50,000 boe/d. Putumayo Blocks - Development & Exploitation: Acquired 50% W.I. under business collaboration agreements in the Orito, Area Sur, Occidente and Nororiente Blocks in the Putumayo Basin of Colombia via an initial work plan commitment with no up-front acquisition cost. Phase I: Parex receives 50% of future incremental production through funding development wells and implementing secondary recovery programs; expenditure commitment for carry capital by Parex of approximately $175 million on a gross capital program of roughly $350 million, with the Company having the flexibility to shift commitment carry capital to other Parex and Ecopetrol partnerships as required. Assets are expected to receive approximately $20 to $50 million of budgeted capital expenditures in the FY 2025 Parex program to begin Phase I development and exploitation activity, with investment level depending on access timing; the Company currently expects initial access to be approximately Q2 2025. Phase II: Upon completion of Phase I, or after three years, thereafter Parex will receive 50% of all base existing production, in addition to the 50% of incremental production, with an ongoing 3% capital carry in favour of Ecopetrol; current average production from the base existing producing wells is approximately 5,800 bbl/d of oil. Dated December 10, 2024, GLJ has recognized Company interest of: Proven reserves of 10 million barrels and future development capital of approximately $167 million. Proved plus probable reserves of 18 million barrels and future development capital of approximately $171 million. Provides low-risk development drilling inventory with gross 2P future locations of approximately 19, in addition to existing producing wells and re-complete opportunities. The Putumayo Blocks currently produce and are prospective for light & medium crude oil, with an average API generally above 25 degrees . In addition to development opportunities, the acquired Putumayo Blocks add near-field exploration prospects in proven plays that materially enhance Parex's portfolio. Farallones Block - Llanos Foothills: Acquired 50% W.I. and operatorship in the Farallones Block in the Llanos Foothills of Colombia, in exchange for drilling the Farallones exploration well, as well as the further expenditure commitment for carry capital of approximately $30 million on a gross capital program of roughly $60 million; commitment carry capital can be executed until 2029, with the Company having flexibility to shift commitment carry capital to other Parex and Ecopetrol partnerships as required. Extends Parex's Foothills position and includes Farallones, which is an exploration prospect that offsets Cusiana by approximately 70 kilometres and represents one of the highest-ranking prospects in Parex's high-impact, big 'E' exploration portfolio. In the FY 2025 Parex program, plan to commence initial access work to prepare for civil works activity and the expected spud of Farallones in 2026.

08:21 EST Asset Entities approved by TikTok as official TikTok Shop Partner - Asset Entities announced it has been approved as an official TikTok Shop Partner. After acquiring the TikTok Shop community, TikTok Money Machine, in November 2024, TikTok's Global E-Commerce Partner Team notified Asset Entities late Monday afternoon that the Company is approved as an official TikTok Shop Partner. Asset Entities will now work with TikTok to connect brands with creators and help them collaborate further in the affiliate marketing space.

08:18 EST Eli Lilly announces results from the Phase 3 EMBER-3 study - Eli Lilly and Company announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor degrader, or SERD, in patients with estrogen receptor positive human epidermal growth factor receptor 2 negative, or HER2- advanced breast cancer, or ABC, whose disease progressed on a prior aromatase inhibitor, or AI, with or without a CDK4/6 inhibitor. Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, as monotherapy in patients with an ESR1 mutation versus standard of care endocrine therapy, or SOC ET, reducing the risk of disease progression or death by 38%. Imlunestrant in combination with Verzenio reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients. These results were published in The New England Journal of Medicine and will be shared in a late-breaking oral presentation at the San Antonio Breast Cancer Symposium. In the EMBER-3 study, patients were randomized 1:1:1 to receive imlunestrant alone, SOC ET, or the imlunestrant-abemaciclib combination. Randomization was stratified by prior CDK4/6 inhibitor use, the presence of visceral metastases and geographic region. Imlunestrant significantly improved PFS versus SOC ET in patients with an ESR1 mutation. In patients with an ESR1 mutation, median PFS was 5.5 months with imlunestrant versus 3.8 months with SOC ET; p-valueless than0.001]. The overall response rate, or ORR, with imlunestrant was 14% compared to 8% with SOC ET in patients with an ESR1 mutation. In all patients, the median PFS was 5.6 months with imlunestrant versus 5.5 months with SOC ET; p-value 0.12] and did not reach statistical significance. Consistent with preclinical data demonstrating central nervous system penetrance and CNS-activity of imlunestrant, CNS progression rates from a post-hoc analysis were lower with imlunestrant in all patients, as well as patients with an ESR1 mutation, however, these analyses are limited by low event numbers and lack of mandated serial asymptomatic CNS imaging in all patients. Imlunestrant-abemaciclib significantly improved PFS compared to imlunestrant in all patients, regardless of ESR1 mutation status, with median PFS of 9.4 months for imlunestrant-abemaciclib versus 5.5 months for imlunestrant alone. The PFS benefit of the combination was consistent across subgroups, regardless of ESR1 mutation, or PI3K pathway mutation status, and including in patients who had previously received CDK4/6 inhibitor treatment. In all patients, the ORR with imlunestrant-abemaciclib was 27% compared to 12% with imlunestrant alone. Overall survival results for EMBER-3 were immature at the time of analysis. The trial will continue to assess OS as a secondary endpoint.

08:18 EST Atossa Therapeutics announces resuts from Phase 2 KARISMA-Endoxifen study - Atossa Therapeutics announced full results from its Phase 2 KARISMA-Endoxifen trial conducted at the Karolinska Institute in Stockholm, Sweden. The data, which will be presented during a Poster Spotlight Session at the 2024 San Antonio Breast Cancer Symposium, highlight the potential of low-dose (Z)-endoxifen to significantly reduce mammographic breast density, MBC, a key risk factor for breast cancer, while demonstrating a favorable safety profile. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Results showed that the 1 mg dose of (Z)-endoxifen reduced MBD by 17.3 percentage points, while the 2 mg dose achieved a reduction of 23.5 percentage points, compared to a minimal change in the placebo group of 0.27 percentage points. Plasma concentrations for (Z)-endoxifen were measured at 4.8 ng/mL and 9.7 ng/mL for the 1 mg and 2 mg arms, respectively, highlighting the effectiveness of the lower dose in achieving significant reductions.

08:18 EST ProPhase Labs secures private equity backing, nears lozenge deal - ProPhase has secured an agreement with a billion-dollar global private equity fund, providing flexible, low-interest rate debt financing as needed. Based on the current operating plans and financial forecasts, the Company believes that the aforementioned debt financing arrangement will eliminate the necessity for future equity financing in the near term and provides the Company with the strategic freedom to focus on and grow its core businesses until a meaningful liquidity event occurs and/or until the Company achieves profitability. Additionally, ProPhase will explore opportunities with the fund to distribute its ProPhase TK supplements-Legendz XL, Legendz Triple Edge, and the forthcoming Equivir-throughout Asia. Equivir is a clinically tested dietary supplement that serves as an immune booster, both prophylactically and therapeutically. The Company is entering the final phase of contract negotiations with a major lozenge brand. This partnership would fully utilize Pharmaloz's forthcoming high-tech production line #2, set to be one of North America's most advanced lines, offering enhanced automation, efficiency, and energy savings. For Line #1, the Company currently estimates a 12-month forward-looking run rate of $15+ million in revenues and a projected $5+ million in net earnings at Pharmaloz. The new contract, if consummated, would add up to $35 million in additional revenues annually. By late 2025, assuming full utilization of production lines #1 and #2, annualized revenue run-rates may approach $50 million, with projected net earnings of between $8 and $10 million entering 2026. To support these Pharmaloz growth initiatives, ProPhase has hired Jay Schwartz, a 30-year veteran in the consumer health sector. Mr. Schwartz will play a key role in finalizing the large lozenge contract, overseeing the installation of line #2, and preparing it for full-scale utilization. Furthermore, he will assist the Company as we actively pursue strategic alternatives including a potential sale of Pharmaloz.

08:16 EST Ageagle Aerial Systems receives Green UAS certification - AgEagle Aerial Systems has been granted Green UAS certification from the Association for Uncrewed Vehicle Systems International. Green UAS is an expanded framework for certification built off the Defense Innovation Unit's Blue UAS certification program but designed for non-defense and commercial companies looking to verify their compliance with cybersecurity and supply chain standards. Green UAS cybersecurity and supply chain risk assessments are held to the same standard as those in Blue UAS but also are expanded upon in the Green UAS program. The certification validates commercial small UAS as cyber-secure and will provide a wider variety of secure UAS than the current Blue 2.0 list to conduct mission sets.

08:15 EST VERSES AI releases latest version of Genius - VERSES AI announces the release of a software update of its flagship product Genius to its beta program participants. "Our flagship product, Genius, features a collection of tools designed for developing and deploying Genius agents, assisting machine learning practitioners-such as programmers, coders, engineers, and researchers-in tackling unprecedented AI challenges," said Hari Thiruvengada, CTO. "In this release, we are introducing powerful enhanced reasoning and planning capabilities, accompanied by comprehensive explainability, to our toolkit. Furthermore, we have improved the user experience by providing a new model building interface with simplified tutorials and deployment processes based on initial feedback from early beta users. This is merely the beginning of our commitment to continuous improvement. Looking ahead, our product roadmap is strategically designed to deliver additional valuable and advanced capabilities to our customers shortly." This release will initially be available to existing beta partners, select journalists, and industry experts.

08:13 EST Nano Nuclear Energy appoints Norato as Director of Nuclear Facilities - NANO Nuclear Energy announced that it has appointed Michael Norato, Ph.D., as its Director of Nuclear Facilities and Infrastructure. Norato has over 25 years of experience in chemical separations technologies involving used nuclear fuel and radioactive waste processing, as well as experience in commercial nuclear industry regulation and nuclear facility decommissioning.

08:13 EST Greif is hosting a 2024 Investor Day - Greif is hosting an Investor Day in New York City, Wednesday, December 11, 2024. Ole Rosgaard, Chief Executive Officer, Larry Hilsheimer, Chief Financial Officer, and the Greif Executive Leadership Team will provide an in-depth review of the Company's Build to Last strategy and future growth plans. "Our entire leadership team is excited to meet with investors for this in-depth strategic review." said Ole Rosgaard, President and Chief Executive Officer. "We view our investors as key customers to us in our pursuit to being the best customer service company in the world. We are excited today to demonstrate to them how we are accelerating growth, profitability and resiliency in our business to meet the challenges of tomorrow."

08:12 EST Hershey down 4.6% premarket after Mondelez says 'committed' to bolt-on M&A

08:10 EST Enphase Energy begins shipments of IQ8X, IQ8 commercial microinverters - Enphase Energy announced initial shipments of IQ8X Microinverters and IQ8P-3P Commercial Microinverters supplied from manufacturing facilities in the United States with higher domestic content than previous models. The microinverters have SKUs with a "DOM" suffix, indicating an increased amount of domestic content.

08:09 EST Apple Intelligence now features 'seamless support for ChatGPT' - Apple announced the release of iOS 18.2, iPadOS 18.2, and macOS Sequoia 15.2, introducing a brand-new set of Apple Intelligence features for iPhone, iPad, and Mac, which builds on the first set of capabilities already introduced. "Apple Intelligence is the easy-to-use personal intelligence system that delivers helpful and relevant intelligence while taking an extraordinary step forward for privacy in AI. Now users can explore creative new ways to express themselves visually with Image Playground, create the perfect emoji for any situation with Genmoji, and make their writing even more dynamic with new enhancements to Writing Tools. Building on Apple Intelligence, users with an iPhone 16 or iPhone 16 Pro can instantly learn more about their surroundings with visual intelligence with Camera Control. And now with ChatGPT integrated into Writing Tools and Siri, users can tap into ChatGPT's expertise without having to switch between apps, helping them get things done faster and easier than ever before," the company stated. Reference Link

08:09 EST Phathom Pharmaceuticals submits Citizen Petition to FDA - Phathom Pharmaceuticals announced it has submitted a Citizen Petition, CP, with the U.S. Food and Drug Administration, FDA. The petition formally requests correction of the Orange Book listings for VOQUEZNA 10 mg and 20 mg tablets to accurately reflect the full 10-year NCE exclusivity period until May 3, 2032. The update would align the VOQUEZNA tablets Orange Book listings to reflect the same period of NCE exclusivity that was granted upon approval of vonoprazan-based VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK in May 2022. The statutory 10-year exclusivity period encompasses the five-year standard exclusivity period for NCEs as extended by the additional five years by operation of the Generating Antibiotic Incentives Now, GAIN, Act. As VOQUEZNA tablet products contain the same drug substance with the active moiety, vonoprazan, they should be entitled to the same protection.

08:08 EST DOMA Perpetual Capital to nominate four candidates to Pacira's board - DOMA Perpetual Capital Management, which beneficially owns approximately 4.14% of the outstanding shares of common stock of Pacira BioSciences, announced that it intends to nominate four highly-qualified, independent director candidates at the company's 2025 annual meeting of stockholders, and stated that it has hired Olshan Frome Wolosky LLP as counsel to represent it in its dealings with the company. DOMA further stated that it believes strongly in the value of the company's intellectual property and that the company's stock is grossly undervalued and urged the company to immediately commence a stock tender offer for 10M shares using its substantial cash on hand, and then execute its already-approved $150M buyback program using the company's healthy and growing free cash flow.

08:08 EST LKQ Corp. continues board refreshment, appoints Metcalf as new director - LKQ Corporation announced that it has appointed James Metcalf to its Board of Directors as a new independent director effective December 11, 2024, as part of the Board's ongoing refreshment process. The Company also announced that Dominick Zarcone has decided not to stand for re-election and will retire from the Board when his term expires in connection with the Company's 2025 Annual Meeting. Following the 2025 Annual Meeting, the Board will consist of ten directors, nine of whom are independent.

08:07 EST NanoVibronix gets $12M purchase deal for PainShield, extends distribution pact - NanoVibronix announced it has renewed its exclusive distribution agreement with Ultra Pain Product or UPPI for the distribution of the Company's PainShield for another five years. Brian Murphy, CEO of NanoVibronix, commented, "We are thrilled to extend our partnership with Ultra Pain Products for another five years and secure a minimum purchase commitment of our products valued at $12M. UPPI's impressive growth, transition into manufacturing and dedication to innovation align perfectly with our values and goals. Their ability to deliver affordable and effective solutions to patients makes them an ideal partner to help us continue to make a difference." The Company's decision to renew the distribution agreement comes in recognition of UPPI's remarkable growth over the past four years and its evolution into a leading force in the non-opioid pain management and injury recovery industry. The renewed agreement underscores the continued collaboration between the two companies and ensures that NanoVibronix's proprietary PainShield product is a part of Ultra Pain Products' expanding portfolio of proven and groundbreaking technologies. Ari Alayev, President of Ultra Pain Products, commented, "We are honored to continue our exclusive distribution agreement with NanoVibronix.

08:06 EST Vera Bradley board approves additional $30M repurchase authorization - The Board of Directors has approved an additional $30.0 million repurchase authorization which commences at the expiration of the current authorization and extends for three years. The Company does not currently plan to purchase shares under the remaining 2024 Share Repurchase Program, but anticipates utilizing the newly approved share repurchase authorization in the future depending on market conditions and the Company's cash position.

08:05 EST Clear Channel Outdoor unit awarded 10-year contract with WCAA - Clear Channel Outdoor's Airports Division, the Americas-based airports business of Clear Channel Outdoor Holdings, announced Wayne County Airport Authority awarded it a 10-year contract to continue evolving their state-of-the-art advertising and sponsorship program at Detroit Metropolitan Wayne County Airport. This win comes via a competitive RFP process and continues a partnership Clear Channel Outdoor began with Wayne County Airport Authority in 2003. The new contract includes Chandler Campbell & Daschle, Bayview Electric, and McConnell Communications as local subcontractors.

08:04 EST Moleculin Biotech announces publication of abstract on Annamycin - Moleculin Biotech announced the online publication of its abstract titled, "Annamycin, a non-cardiotoxic anthracycline, demonstrates unique organotropism and activity against Ara-C and Venetoclax resistant AML," as part of the ASH Annual Meeting held December 7-10, 2024, in San Diego, CA. For the preclinical study, subsets of parental, cytarabine, or Ara-C,-resistant, and Venetoclax, or VEN,-resistant AML cell lines were treated with Annamycin at 0-3000 nM in vitro, alone, or +/- VEN and +/- Ara-C. Treatment of naive and heavily pretreated relapsed/refractory primary AML patient samples were also evaluated. The impact of DOX and Annamycin was further tested on established cultures of rat H9c2 cardiomyoblasts derived from ventricular tissue of myocardium and on human cardiomyocytes derived from induced pluripotent stem cells, or iPSCs. RTCA CardioECR was applied to probe-free determination of viability, contractility, and electric potential. Finally, anti-leukemic efficacy of Annamycin in combination with Ara-C was evaluated in an aggressive, TP53 null FLT3-ITD mutated syngeneic AML Turqoise model, with extensive evaluation of tumor burden in bone marrow, spleen, lungs, and liver by fluorescence imaging. PK and tissue-organ distribution of Annamycin were analyzed in naive mice and rats versus DOX. Highlights include: Annamycin displayed synergy with Ara-C and VEN in reducing viability in parental treatment naive cell lines and in Ara-C-and VEN-resistant cell lines; Annamycin showed no apparent toxicity in vivo. Parallel comparison of Annamycin and DOX at 8 mg/kg for 7 weeks exhibited a favorable toxicity profile for Annamycin, with no evidence of cardiotoxicity ex vivo. DOX treated mice demonstrated significant weight loss and increased levels of lactate dehydrogenase in blood serum. Histopathological evaluation of heart tissue postmortem revealed mild cytoplasmic vacuolation of cardiac myocytes only in DOX-treated cohorts; Evaluation of human cardiomyocytes treated with Annamycin or DOX revealed a limited impact of Annamycin on human cardiomyocyte contractility, viability, and electric potential up to the highest tested dose of 1.5 uM as assessed by RTCA, in opposition to heavily perturbed contractility induced by DOX at 0.5 uM; Annamycin's ability to extend survival was potentiated in combination with Cytarabine; Annamycin was well tolerated by the animals even at schedules exceeding the therapeutic dosage of 4 mg/kg. Ex vivo pathology examination confirmed no toxicity to the murine heart/myocardium, similar to patients in clinical trials. The Company is advancing the development of Annamycin in a Phase 3 pivotal trial evaluating AnnAraC for the treatment of AML patients who are refractory to or relapsed after induction therapy This Phase 3 "MIRACLE" trial will be a global trial, including sites in the US. The Company remains on track to initiate patient treatment in the Q1 of 2025. Annamycin currently has Fast Track Status and Orphan Drug Designation from the FDA for the treatment of relapsed or refractory acute myeloid leukemia, in addition to Orphan Drug Designation for the treatment of soft tissue sarcoma. Furthermore, Annamycin has Orphan Drug Designation for the treatment of relapsed or refractory acute myeloid leukemia from the European Medicines Agency.

08:03 EST Brookfield Asset Management makes minority equity investment in SVP - Tiger Infrastructure Partners announced that Brookfield Asset Management and its institutional partners has made a minority equity investment in its portfolio company Strategic Venue Partners. Tiger also announced a material upsizing of SVP's existing Revolving Credit Facility with current and additional commercial bank lenders. Together, these strategic financing transactions position SVP to capitalize on growing demand for its essential in-building wireless infrastructure.

07:56 EST BriaCell presents OS data in MBC patients treated with Bria-IMT/CPI regimen - BriaCell Therapeutics is pleased to showcase its survival and clinical benefit data in MBC patients, including those with CNS metastases, treated with the Bria-IMT plus CPI regimen. The data is featured in BriaCell's "Spotlight" poster presentation session, at the 2024 San Antonio Breast Cancer Symposium held at Henry B. Gonzalez Convention Center, San Antonio, TX. The data presented is from the fully enrolled BriaCell Phase 2 combination study of Bria-IMT plus CPI. An aggregate of 54 MBC patients were enrolled in the study - all treated with the Bria-IMT combination regimen. Data is available on all 54 of these heavily pre-treated metastatic breast cancer patients. Of these 54 patients, 37 were treated with the formulation currently under investigation in BriaCell's ongoing pivotal Phase 3 study in metastatic breast cancer. Final median overall survival calculation for the patients in the Phase 2 portion of the study is pending, as most of these patients remain alive over 1 year following their start on the study. No Bria-IMT related discontinuations have been reported to date.Title: Overall survival results of Bria-IMT allogenic whole cell-based cancer vaccine: Bria-IMT regimen's OS and tolerability in MBC patients: Median overall survival to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation double that of comparable patients in the literature. Final Phase 2 OS calculation is pending as many patients remain alive well over 1 year after starting the study. Median overall survival for patients who received the Phase 3 formulation in the Phase 2 portion of the study who also developed an immune response to the vaccine as measured by delayed-type hypersensitivity not yet reached with greater than1 year follow-up. 13.7 months median OS in MBC patients with central nervous system /intracranial tumors treated with the Bria-IMT regimen with or without a CPI. Objective response rates and clinical benefit rates were observed across all MBC patient subsets, but positive clinical outcomes were more prominent in HER2+ and HR+/HER2- patient subsets. Bria-IMT regimen was well-tolerated and produced clinical benefit in heavily pretreated MBC patients. Patients who developed a DTH response had lower neutrophil to lymphocyte ratio, suggesting improved clinical benefit in these patients. Delayed-type hypersensitivity response, and circulating tumor cells levels were significantly different between patients who responded vs those who did not respond to the Bria-IMT combination regimen. In conclusion, clinical findings to date support the potential safety and efficacy of Bria-IMT, along with its potential use in CNS metastases, as well as the possible use of biomarkers to predict clinical outcomes in BriaCell's ongoing pivotal Phase 3 study in MBC. Title: Identification of antigenic determinants in SV-BR-1 derived cellular breast cancer vaccines: Summary: BriaCell successfully identified immunogenic peptides in patients treated with Bria-IMT, a cell-based cancer vaccine, and showed Bria-IMT's ability to produce a targeted immune response against tumor antigens. Key immunogenic peptides detected included those with post-translational modifications, such as citrullination and cysteinylation, an important type of neoantigen that may be shared across many patients with cancer. Highlighted the advantage of cell-based cancer vaccines over RNA and peptide-based vaccines including their ability to present a broad and diverse repertoire of antigens. Cell-based cancer vaccines also display unknown, patient-specific neoantigens that are hard to reproduce with RNA or peptide vaccines. Diverse antigen presentation produces a robust, polyclonal immune response, engaging both CD8+ and CD4+ T cells against multiple tumor target. In conclusion, scientific data presented suggests that the unique mechanism of cell-based cancer vaccines may reduce cancer cells' immune escape and may potentially lead to strong and long-lasting clinical outcomes in cancer patients. Title: PD-L1 upregulation in circulating tumor associated cells predicts for clinical outcomes in a phase I/II clinical trial using SV-BR-1-GM vaccine with the checkpoint inhibitor retifanlimab in metastatic breast cancer patients, an interim analysis: Summary: Interim analysis after at least one year of Bria-IMT plus CPI regimen shows the following: Significantly lowered levels of circulating tumor cells and cancer associated macrophage-like cells in 40% of heavily pre-treated MBC patients. Lower CTCs/CAMLs levels were significantly correlated with better survival outcomes. Bria-IMT appeared to increase PD-L1 levels in 15 patients which correlated with better clinical responses to combination treatment with the anti-PD-1 check point inhibitor retifanlimab. In conclusion, clinical data support the combination regimen in our ongoing pivotal Phase 3 study and suggests CTCs and CAMLs and PD-L1 levels may be relevant indicators of clinical outcome in MBC patients treated with Bria-IMT plus CPI. Abstract Title: ASTRO-VAC CNS: Bria-IMT in the management of tumor agnostic metastatic CNS lesions: Results: The poster provides the details of a planned Phase 2 study design expanding the use of Bria-IMT + CPI to tumor agnostic cancer patients with central nervous system metastasis.

07:47 EST Jacobs selected by Metro Vancouver for Coquitlam Lake Water Supply Project - Jacobs was selected by Metro Vancouver, a regional district in British Columbia, Canada to provide program management services for the Coquitlam Lake Water Supply Project. The project will expand capacity for accessing, treating and distributing water from Coquitlam Lake, the region's largest drinking water source, while increasing the system's resilience to climate change. The infrastructure includes building a state-of-the-art intake facility, a 5.3-mile water supply tunnel and a new treatment plant to serve the region's 2.7M residents and meet future demand. As the program manager, Jacobs will oversee permitting, design, project controls and construction of the critical water infrastructure as well as deliver supporting technical services and a treatment pilot study.

07:38 EST Netlist announces patent upheld by Patent Trial and Appeal Board - Netlist (NLST) announced that its U.S. Patent Nos. 10,268,608 was upheld by the Patent Trial and Appeal Board and found not to be invalid. This patent was part of a November 2024 jury verdict in the United States District Court for the Eastern District of Texas where Netlist won a $118M damages award against Samsung (SSNLF). Netlist filed a motion with the EDTX for a preliminary and permanent injunction against Samsung regarding all infringing products related to the '608 patent, which includes Samsung DDR4 LRDIMMs. The court has scheduled a hearing on Netlist's injunction motion for December 23, 2024.

07:36 EST Datametrex receives C$250K purchase order - Datametrex AI has received purchase orders of approximately C$250K from its IT services on December 9, 2024. The estimated cost to deliver is approximately $188K, resulting in a gross profit margin of approximately 26%.

07:35 EST Scilex announces Phase 2 trial for obesity enrolling U.S. patient cohort - Scilex Bio announced ongoing Phase 2 trial for obesity currently enrolling with U.S. patient cohort to be added in 2025 and positive topline results from the recently completed Phase 1 trials for oral KDS2010, a novel oral tablet small molecule agent. The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and efficacy of KDS2010 in approximately 75 overweight or obese patients currently enrolling in South Korea with a cohort in U.S. to be added in 2025. KDS2010 has shown promising preclinical results with a novel mechanism of blocking MAO-B-dependent aberrant GABA production in reactive astrocytes and eliminates neuronal inhibition in Lateral Hypothalamic Area, stimulating metabolism and energy expenditure without affecting appetite. KDS2010 pharmacokinetics, lack of food effect, safety and dose selection have been characterized in Single Ascending Dose and Multiple Ascending Dose Phase 1 clinical trials with 88 healthy young adults and elderly subjects, demonstrating favorable safety and tolerability and adequate pharmacokinetics for once-daily dosing

07:33 EST Arrowhead announces interim results from ARO-CFB study - Arrowhead announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference, or RNAi, therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented at the 8th Complement-Based Drug Development Summit being held in Boston. In the ongoing AROCFB-1001 study, ARO-CFB achieved the following key results in normal healthy volunteers as of the interim data cutoff: ARO-CFB led to dose dependent reductions in circulating CFB protein by up to 90% with greater than 3 months duration; 90% mean reduction achieved after a single dose of 400 mg; 90% mean reduction achieved after two doses of 100 mg; single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway activity based on Wieslab AP; 100% mean reduction achieved by week 4 after a single dose at both 200 mg and 400 mg doses; 92% and 100% mean reductions were achieved after two doses at 100 mg and 200 mg, respectively. Single and multiple doses of ARO-CFB led to near complete inhibition of alternative pathway hemolytic activity, measured by AH50. ARO-CFB has been generally well-tolerated to date with safety data supportive of further clinical development. There have been no treatment emergent adverse events leading to study or study drug discontinuation with most TEAEs being mild in severity.

07:32 EST Royal Caribbean raises quarterly dividend 38% to 55c per share - The Board of Directors of Royal Caribbean Cruises declared a quarterly dividend of 55c per common share payable on January 13, 2025 to shareholders of record at the close of business on December 27, 2024. This increase reflects the company's continuing efforts to enhance shareholder returns.

07:31 EST Abaxx Technologies to launch Nickel Sulphate futures on January 10 - Abaxx Technologies will launch Nickel Sulphate futures, the first of its battery metals products, on January 10, 2025. Abaxx Nickel Sulphate futures are designed to deliver better price discovery and risk management tools for market participants in this battery metal critical to the energy transition to a lower carbon economy. Participants in the global nickel market are seeking better pricing solutions that can encompass refined metal and new streams of nickel products flowing into the fast-growing electric vehicle battery sector. A physically-settled nickel sulphate contract, rather than a contract for Class 1 refined nickel, can better capture the fastest-growing segment of the global market. This Abaxx Nickel Sulphate Singapore futures contract is a US dollar-denominated, 5 tonne nickel contained, DAP contract physically deliverable in Singapore.

07:20 EST Macy's identifies material weakness in internal control over financial reporting - In a regulatory filing, Macy's said that in the course of preparing the company's financial statements for the interim period ended November 2, 2024, management identified a material weakness in its internal control over financial reporting related to the design of existing internal control activities involving manual journal entries over delivery expenses and certain other non-merchandise expenses, and the reconciliation of the related accrued liabilities. The company identified that a single employee, who is no longer with the company, intentionally made erroneous accounting entries and falsified underlying documentation, to understate delivery expenses from the fourth quarter of 2021 through the third quarter of 2024. The material weakness was the result of deficiencies in the design of controls over delivery expense and certain other non-merchandise expenses, and the related accrued liabilities, whereby the design of the controls did not consider the potential for employee circumvention of these controls. The design of these controls included failures to obtain, or generate and use, relevant, quality information to support the functioning of these controls, including validation of the reliability of the information. The company is committed to addressing the material weakness and has begun to implement changes designed to improve its internal control over financial reporting and to remediate the material weakness, including: Re-evaluating the risk of employee circumvention of controls, including risks surrounding the completeness of delivery expense and certain other non-merchandise expenses and the related accrued liabilities; Re-designing process level control activities that are responsive to the risk of employee circumvention of controls. In light of the material weakness described above, management performed additional analysis and other procedures to ensure that its consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles. As a result of the material weakness in the company's internal control over financial reporting described above, on December 10, 2024 the Audit Committee of the Board of the company determined, based on the recommendation of management following its consultation with the company's independent registered public accounting firm KPMG LLP, that management's report on internal control over financial reporting as of February 3, 2024, included in Item 9A of the Company's Annual Report on Form 10-K for the fiscal year ended February 3, 2024 filed with the SEC on March 22, 2024 should no longer be relied upon.

07:17 EST Exxon Mobil unveils Corporate Plan to 2030, sees $20B share repurchases in 2026 - ExxonMobil announced its Corporate Plan to 2030. The company expects to deliver incremental growth potential of $20B in earnings and $30B in cash flow. On a constant price and margin basis, the company is generating more than $15B in earnings and more than $20B in cash flow vs. 2019, and has delivered structural cost savings of more than $11B year-to-date vs. 2019. Over the next six years, the company expects to generate an additional $20B in earnings potential and $30B in cash flow potential. It plans to grow earnings at a CAGR of 10% and cash flow at 8% and has plans to achieve an additional $7B in structural cost savings by simplifying business processes, optimizing supply chains, further enhancing maintenance turnaround processes, and modernizing information technology and data management systems. The company's capital allocation approach prioritizes competitively advantaged, high-return, low-cost-of-supply investments. In 2025, the company expects cash capital expenditures to be in the range of $27B to $29B, reflecting the first full year of Pioneer in the portfolio and investment to build new businesses with base capex remaining flat. From 2026 to 2030, base capex is consistent, while capex growth is driven by progressing opportunities in new businesses, and a few early-stage large projects in the company's traditional businesses. The reinvestment rate relative to expected cash flow declines 10 percentage points over the plan period. Cash flow and earnings growth generate a further $165B in surplus cash over the plan period driving increased shareholder distributions. ExxonMobil has increased its annual dividend per share for 42 consecutive years, and recently increased its quarterly dividend by 4c per share effective this quarter. The company continues to expect to repurchase shares at a $20B annual pace in 2025, and announced plans for a further $20B of share repurchases in 2026, assuming reasonable market conditions.

07:16 EST ParaZero announces order for drone safety systems from Australian distributor - ParaZero Technologies announced the receipt of an order for its SafeAir systems from a significant distributor specializing in drones and drone technology in Australia. This order highlights ParaZero's growing footprint in the Australian market, built on recent regulatory achievements and strategic partnerships. Collaborating with prominent local distributors has been central to ParaZero's success in the region. By leveraging these partnerships, ParaZero has made its CASA-approved safety systems widely accessible, empowering operators to conduct advanced and safe drone missions.

07:14 EST Boralex, SNGRDC close financing for Hagersville Battery Energy Storage Park - Boralex and its partner, Six Nations of the Grand River Development Corporation announce the closing of a $538M financing for the Hagersville Battery Energy Storage Park, located in Haldimand County, Ontario, Canada. With a capacity of 300 MW / 1,200 MWh, the park will be the biggest battery energy storage project to date in Canada once it reaches commissioning. The financing, which qualifies as a Green Loan, was obtained from a banking syndicate composed of Sumitomo Mitsui Banking Corporation, Canada Branch, KfW Ipex-Bank GMBH, the Korean Development Bank, Credit Industriel et Commercial, New York Branch et DZ Bank, all acting as Joint Lead Arrangers. SMBC also serves as administrative agent, collateral agent, as well as green loan and hedging coordinator, and KfW is designated as the project's technical bank. The Hagersville project financing includes: A $366M construction loan, which will convert into an amortizing term loan over 20 years following the start of commercial operation, scheduled for the fourth quarter of 2025; A $141M bridge loan, allowing the financing of investment tax credits to which the project is eligible. This short-term facility will reduce the amount of equity capital allocated to the project in the short term and thus optimize Boralex's overall capital structure. This loan will be repaid when the investment tax credits are received; A $31M letter of credit facility.

07:12 EST ProQR Therapeutics announces $8.1M in new funding from RSRT - ProQR Therapeutics announced an expansion of its collaboration with the Rett Syndrome Research Trust, RSRT. Building on the initial $1 million research grant announced in January 2024, the expanded partnership includes an additional $8.1 million in funding from the RSRT, for a total of $9.1 million. The funding will support the advancement of AX-2402 into clinical trials. The additional $8.1 million in funding will enable ProQR to accelerate work on RNA editing approaches tailored to the genetic mutations that cause Rett Syndrome. This next phase of the collaboration will focus on optimizing therapeutic candidates targeting the transcription factor Methyl CpG binding protein 2 and advancing them toward clinical development.

07:11 EST PolyPid announces research, development collaboration with ImmunoGenesis - PolyPid announced a new research and development collaboration with ImmunoGenesis, a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel formulations utilizing PolyPid's experience with its proprietary PLEX Technology and ImmunoGenesis' potent STimulator of INterferon Genes, STING, agonist drug candidate to potentially enhance treatment for solid tumors.

07:10 EST GXO Logistics extended its agreement with Guess for nearly a decade - GXO Logistics announced that it has extended its agreement with global lifestyle brand Guess in Italy and the Netherlands for nearly a decade. "We're pleased to extend our partnership with Guess in Europe, which will now span more than two decades," said Paul Mohan, Managing Director, Continental Europe, GXO. "Since the start of our partnership in 2011, we've leveraged our expertise to deploy cutting edge solutions that have enhanced capacity, efficiency, safety and sustainability. Together, we've achieved numerous transformational successes and we're not done yet."

07:09 EST Celcuity presents overall survival data from Phase 1b trial with gedatolisib - Celcuity announced overall survival, OS, data from two patient cohorts evaluated in a Phase 1b trial with gedatolisib, a pan-PI3K/mTORC1/2 inhibitor, in combination with palbociclib and either letrozole or fulvestrant, in patients with HR+, HER2-advanced or metastatic breast cancer. Results will be presented in a poster session at the San Antonio Breast Cancer Symposium, SABCS, being held December 10-13 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The poster presents overall survival data among patients with HR+, HER2- advanced breast cancer who were either treatment-naive or whose disease progressed during prior treatment with a CDK4/6 inhibitor. For the treatment-naive patient cohort, median OS was 77.3 months. For the patients previously treated with a CDK4/6 inhibitor and who received the Phase 3 dose of gedatolisib, median OS was 33.9 months.

07:08 EST Siyata Mobile to relocate manufacturing of PTT devices to U.S. in 2025 - Siyata Mobile announced it will be relocating its current 4G and next generation 5G PTT handset manufacturing operations from China to the United States in 2025. Marc Seelenfreund, CEO of Siyata, said, "We began working on a manufacturing relocation plan earlier this year and are proud to announce today that we expect to begin manufacturing operations in the U.S. in the first quarter of 2025. This is an important strategic move that we believe will open up additional sales opportunities globally, particularly in the U.S., and help us to further scale our business. Users of our devices, especially governmental agencies and first responders, value America manufactured products, but just as important, this move will enable us to shorten delivery lead times and operate within a stronger logistics infrastructure. We are very excited to be making this move and believe it is an important milestone for Siyata."

07:07 EST Monte Rosa Therapeutics presents preclinical data on CDK2 degrader - Monte Rosa Therapeutics announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2, CDK2,-directed molecular glue degrader to treat HR-positive/HER2-negative breast cancer at the 2024 San Antonio Breast Cancer Symposium, held December 10-13 in San Antonio, Texas. The data demonstrate that the company's CDK2-directed MGD, MRT-9643, has superior selectivity compared to clinical-stage CDK2 inhibitors and induced robust downstream CDK2 pathway suppression. When combined with current standard of care therapies, MRT-9643 drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer.

07:07 EST Palantir announces first Warp Speed cohort of companies - Palantir Technologies (PLTR) announced its first Warp Speed cohort, comprised of companies committed to reindustrializing America's manufacturing and production capabilities through advanced AI and technology. The inaugural members include: Anduril Industries, L3Harris (LHX), Panasonic Energy of North America, or PENA, and Shield AI. Palantir's Warp Speed is the manufacturing operating system that provides the speed, flexibility, and security required for the modern manufacturer. Anduril Industries is a leader in autonomous technologies. The company was the first to use the Warp Speed operating system in production as part of the Arsenal OS suite of tools. It powers many workflows to support manufacturing at scale, such as dynamic material resource planning, phasing in of new configurations efficiently, and reducing material and labor variances. L3Harris announced its strategic partnership with Palantir in October. L3Harris is using Warp Speed to close the loop between design, configuration and production, enabling production planning in parallel to ongoing configuration improvements.

07:06 EST Monte Rosa announces closing of global license agreement with Novartis - Monte Rosa Therapeutics (GLUE) announced the closing of the Company's previously announced global exclusive development and commercialization license agreement with Novartis (NVS) to advance VAV1-directed MGDs, including MRT-6160. Under the terms of the agreement, Novartis will obtain exclusive worldwide rights to develop, manufacture, and commercialize MRT-6160 and other VAV1 MGDs and will be responsible for all clinical development and commercialization, starting with Phase 2 clinical studies. Monte Rosa remains responsible for completing the ongoing Phase 1 clinical study of MRT-6160.i Novartis has agreed to pay Monte Rosa $150 million up front. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, as well as tiered royalties on ex-U.S. net sales. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S.

07:05 EST Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial - The European Organisation for Research and Treatment of Cancer and Immunocore Holdings announced the randomization of the first patient in the Phase 3 Adjuvant Trial in Ocular Melanoma, investigating the safety and efficacy of tebentafusp as adjuvant treatment for uveal melanoma. The primary objective of the open-label, international, multicenter trial - led by EORTC - will be to assess whether tebentafusp can prevent or delay relapse in patients with primary ocular melanoma at high risk of relapse, as compared with observation. Tebentafusp is approved for the treatment of HLA-A 02:01-positive adult patients with unresectable or metastatic uveal melanoma in 38 countries, under the brand name KIMMTRAK. The trial is expected to enroll 290 HLA-A*02:01-positive patients with uveal melanoma who have undergone definitive treatment by surgery or radiotherapy. Eligible patients will be randomized 1:1 to one of two arms: tebentafusp [as monotherapy] for six months or until disease relapse, or observation. Secondary objectives include overall survival, safety and tolerability, while exploratory objectives include evaluation of circulating tumor DNA as a marker of residual disease, and a comparison of health-related quality of life.

07:04 EST Macy's says no material impact from delivery expense related investigation - As previously disclosed, during the preparation of the company's unaudited condensed consolidated financial statements for the fiscal quarter ended November 2, the company identified an issue related to delivery expenses in one of its accrual accounts. The company consequently initiated an independent investigation which has now been completed and, following its analysis, determined that there was no material impact to financial results for any historical annual or interim period. As a result of the independent investigation and forensic analysis, the company identified that a single employee with responsibility for small package delivery expense accounting intentionally made erroneous accounting accrual entries to hide approximately $151M of cumulative delivery expenses from the fourth quarter of 2021 through the third quarter of 2024. As previously communicated, the investigation determined that this matter had no impact on the company's reported net cash flows, inventories or vendor payments. The company is revising its historical consolidated financial statements that were impacted by the misstatements to properly reflect delivery expense, the related accrual and tax effects. The total misstatement to delivery expense for the first half of fiscal 2024 amounted to $9M, which was adjusted in total during the third quarter of 2024. Additional details and revised financial information for fiscal years 2021, 2022, and 2023, and quarterly periods for fiscal year 2023 can be found in the company's Form 8-K filed today with the SEC. The company expects to file its Form 10-Q for the fiscal quarter ended November 2 with the SEC on December 12. "We've concluded our investigation and are strengthening our existing controls and implementing additional changes designed to prevent this from happening again and demonstrate our strong commitment to corporate governance," said Spring. "Our focus is on ensuring that ethical conduct and integrity are upheld across the entire organization."

07:02 EST Webuy launches Micky1.0 travel AI tool - Webuy Global announced the launch of its Travel AI, Micky1.0. This tool, available through WhatsApp, helps simplify travel planning and provides personalized support whenever and wherever it is needed. With just a WhatsApp number, users can interact with Micky1.0 to get immediate answers to their travel-related questions. Equipped with an extensive database of travel packages, departure dates, prices, air ticket options, and hotel accommodations, Micky1.0 provides comprehensive information for both group tours and flexible independent travel arrangements. Additionally, integrated API technology allows customers to receive real-time quotes, making trip planning faster and easier than ever. Beyond basic support, Webuy's Micky1.0 offers tailored recommendations based on user preferences for travel dates, destinations, and interests. Customers can also access up-to-date weather information, destination insights, and itinerary suggestions to craft their perfect journey. Additionally, Micky1.0 can support multiple languages using both voice and text messages.

07:00 EST Bausch + Lomb acquires Elios Vision - Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, the first clinically validated, minimally invasive glaucoma surgery, or MIGS, procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb's glaucoma portfolio, which features pharmaceutical and surgical approaches. Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time. The ELIOS technology, which is CE marked, is currently marketed and sold in the European Union. Elios Vision is in the process of pursuing FDA approval for the product. Leerink Partners served as exclusive financial advisor to Elios Vision and Wilson Sonsini Goodrich & Rosati, Professional Corporation served as legal advisor.

07:00 EST Macy's says no material impact from delivery expense related investigation - The company confirms no material impact or restatements to previously filed financial statements following completion of delivery expense related investigation.

06:39 EST Centrus Energy subsidiary awarded $2M contract from U.S. Department of Energy - Centrus Energy announced that its subsidiary, American Centrifuge Operating, has won an award from the U.S. Department of Energy aimed at expanding domestic commercial production of Low-Enriched Uranium, or LEU, to meet the needs of existing and future nuclear reactors. This is the third selection for Centrus under a series of three solicitations from the Department as part of a program to restore America's domestic nuclear fuel supply for LEU and High-Assay, Low-Enriched Uranium. ACO is one of six awardees being announced today for LEU production, with a minimum contract value of $2M and a maximum value for all awardees of $3.4B over a ten-year period. The ultimate dollar amount associated with this award - and the potential scale of the expansion supported - will depend upon task orders subsequently issued by the U.S. Department of Energy to Centrus.

06:33 EST SeaStar Medical sees TAM for SCD in five clinical indications of $25B-$35B - SeaStar Medical estimates a U.S. total addressable market for its proprietary, patented Selective Cytopheretic Device in five clinical indications, subject to U.S. FDA approvals, of $25B-$33B.

06:26 EST Parsons awarded $23M contract by Caltran - Parsons announced that California Department of Transportation, or Caltrans, has selected the company to perform professional and technical services. This $23M contract will provide "as needed" engineering and inspection services for structure construction projects in Caltrans Districts 1, 2, and 3-North. Parsons has performed similar services for Caltrans since 2007, providing construction engineering and inspection services for bridge rehabilitation projects, new bridge construction projects and retaining walls. The project will improve the State transportation system, including roadway rehabilitation, construction of new facilities, and widening, realigning and relocating existing facilities.

06:09 EST Lowe's announces growth, productivity initiatives at investor day - Lowe's is hosting its 2024 analyst and investor conference to provide an update on its growth and productivity initiatives and near-term and long-term financial targets. The company has developed a framework to harness the new power of generative AI through a standardized development process, designed to enhance the customer experience and unlock productivity. The company is now piloting new solutions to empower frontline associates to better serve customers and improve the in-store shopping experience. In early 2025, the company is relaunching its Pro loyalty program as MyLowe's Pro Rewards, designed specifically for the small-to-medium Pro. Additionally, Pro customers who shop with their MyLowe's Pro Rewards Credit Card will save 5% every day on eligible purchases. Lowe's plans to open 10-15 stores per year over the next several years in fast-growing markets in the U.S. To better serve customers living in rural communities, Lowe's is planning to extend its rural assortments to 150 more stores, bringing everything needed for farm and home under one roof.

06:05 EST BitFuFu enters 10-year lease agreements for two Bitcoin mining facilities in U.S - BitFuFu announced it has entered into 10-year exclusive lease agreements for two Bitcoin mining facilities with a combined capacity of 33 megawatts in the U.S. The lease agreements grant BitFuFu the option to acquire a majority stake in both mining facilities. The lease of both mining facilities marks the next step in BitFuFu's transition from an asset-light strategy to one that manages a diverse and robust portfolio of Bitcoin mining infrastructure. BitFuFu has set a target of adding 1 GW of capacity by the end of 2026. With the addition of the two mining facilities, BitFuFu is rapidly executing on this target with over 110 MW now residing in sites owned or operated by the company. The two mining facilities, with hosting capacity of 22 MW and 11 MW, respectively, will provide BitFuFu with the potential to add 2EH/s of mining capacity and power costs averaging as low as $0.042 per kilowatt-hour. The company has been managing self-mining and cloud-mining operations at these facilities for approximately one year and was highly satisfied with the consistent uptime, cost-effectiveness, and operational stability.

06:02 EST European Wax Center appoints Chris Morris as CEO - European Wax Center (EWCZ) announced that its Board of Directors has appointed Chris Morris as CEO and Chairman of the Board, effective January 8, 2025. Morris succeeds David Berg, who will step down as CEO. Berg will remain a member of the Board and work closely with Morris in this role. Morris brings more than 25 years of experience operating, developing and reinvigorating consumer brands, including franchise businesses. Most recently, he was CEO of Dave & Buster's (PLAY), an owner and operator of entertainment and dining venues, where he led the opening of 30 new locations and established an international expansion pipeline during his tenure. He previously served as CEO of Main Event, overseeing a period of significant revenue, profitability and unit growth, in addition to its successful 2022 merger with Dave & Buster's. Prior to Main Event, Morris served as president of California Pizza Kitchen, where he played a key role in the revitalization of the 32-year-old brand, returning it to positive comparable store sales.

05:10 EST Faraday Future announces insourcing of FF 91 2.0 vehicle seats - Faraday Future announced that it is insourcing the manufacturing of its FF 91 2.0 vehicle seats. It also continues to work to optimize its global supplier network and set up a supplier base for the Faraday X brand.